89Bio Inc ( (ETNB) ) has released its Q2 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardiometabolic diseases, with its lead candidate being pegozafermin. In its second quarter of 2025 financial report, 89bio highlighted its ongoing commitment to advancing its Phase 3 trials for pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company expects to release topline data for its ENTRUST trial in SHTG in early 2026, and for its ENLIGHTEN trials in MASH in 2027 and 2028. Financially, 89bio reported cash and equivalents of $561.2 million as of June 30, 2025. The company experienced an increase in research and development expenses, primarily due to the advancement of its Phase 3 trials and the construction of a commercial-scale production facility. This led to a net loss of $111.5 million for the quarter, compared to a $48.0 million loss in the same period last year. Looking forward, 89bio remains focused on executing its clinical development plans, with the potential for accelerated approval of pegozafermin in the future.